Table 3. Characteristics of the 3 included studies on visfatin.
| BMI (mean ± SD) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Author | Year | Country | Sample size | Age (mean ± SD) | Pre-Met | Post-Met | Inclusion/exclusion criteria | Study design | LOE | Therapy duration (month) | Daily dose (mg) |
| Ozkaya M [40] | 2008 | Turkey | 19 | 25.1 ± 3.8 | 27.1 ± 1.7 | 26.1±1.6 | H | SCT | 2 | 3 | 1700 |
| Charles AS [42] | 2007 | Germany | 35 | 24.7 ± 4.8 | 29.3 ± 6.5 | 28.6±7.2 | H | RCT | 1 | 6 | 1700 |
| İlhan T [43] | 2010 | Turkey | 24 | 25.21±5.99 | 31.69 ±6.52 | 30.7±6.65 | H | SCT | 2 | 6 | 1700 |
Abbreviations: SD, standard deviation; BMI, body mass index; H, have; LOE, level of evidence; SCT, self-control trials; RCT, randomized controlled trials.